GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » YoY EBITDA Growth

Medincell (XPAR:MEDCL) YoY EBITDA Growth : 60.09% (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Medincell YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Medincell's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was 60.09%.

Medincell's EBITDA per Share for the six months ended in Sep. 2023 was €-0.18.

Medincell YoY EBITDA Growth Historical Data

The historical data trend for Medincell's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell YoY EBITDA Growth Chart

Medincell Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
YoY EBITDA Growth
Get a 7-Day Free Trial -109.46 7.70 22.36 -23.50 -21.69

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.21 -32.94 -7.56 -34.51 60.09

Medincell YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Medincell's YoY EBITDA Growth for the fiscal year that ended in Mar. 2023 is calculated as:

YoY EBITDA Growth (A: Mar. 2023 )
=(EBITDA per Share (A: Mar. 2023 )-EBITDA per Share (A: Mar. 2022 ))/ | EBITDA per Share (A: Mar. 2022 ) |
=(-1.049--0.862)/ | -0.862 |
=-21.69 %

Medincell's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (Q: Sep. 2023 )
=(EBITDA per Share (Q: Sep. 2023 )-EBITDA per Share (Q: Sep. 2022 )) / | EBITDA per Share (Q: Sep. 2022 )) |
=(-0.176--0.441)/ | -0.441 |
=60.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medincell YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Medincell's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » YoY EBITDA Growth
Comparable Companies
XPAR:AELIS XPAR:IVA XPAR:GNFT XPAR:IPH XPAR:TNG XPAR:DBV XPAR:NANO XPAR:ALSEN XPAR:ADOC XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MEB:Germany
Address
3 rue des Freres Lumiere, Jacou, FRA, 34830
Website
https://www.medincell.com
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines